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Open access under CC BYA forced switch to a lower ISO tar yield cigarette was used in a clinical study, conducted in Germany, that
compared two methods of estimating exposure to cigarette smoke. Pre- and post-switch estimates of
Mouth Level Exposure (MLE) to nicotine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), pyr-
ene and acrolein were obtained by chemical analysis of spent cigarette ﬁlters for nicotine content. Sim-
ilarly, pre- and post-switch estimates of uptake of these smoke constituents were achieved by analysis of
corresponding urinary biomarkers of exposure (BoE): total nicotine equivalents; total 4-(methylnitrosa-
mino)-1-(3-pyridyl)-1-butanol (NNAL); total 1-hydroxypyrene (1-OHP), and 3-hydroxypropyl-mercaptu-
ric acid (3-HPMA), plus the nicotine metabolite cotinine, in plasma and saliva. Three hundred healthy
volunteers were recruited comprising 100 smokers of each of 9–10 and 4–6 mg ISO tar yield cigarettes
and 50 smokers of 1–2 mg ISO tar yield cigarettes and 50 non-smokers. Fifty smokers of each of the 9–
10 and 4–6 mg ISO tar yield cigarettes took part in the switching aspects of this study whilst the remain-
ing smokers formed non-switching control groups who smoked their usual ISO tar yield cigarette
throughout the study. After 5 days, all subjects were admitted into a clinic where baseline measures of
MLE and BoE were obtained. The 10 mg switching group was then switched to the 4 mg ISO tar yield cig-
arette and the 4 mg ISO tar yield switching group switched to the 1 mg cigarette. Subjects returned home
for 12 days, continuing to smoke the supplied cigarettes before being readmitted into the clinic where
samples were collected for MLE and BoE analysis. Changes in daily exposure estimates were determined
on a group and individual basis for both methods. The pre- to post-switch directional changes in MLEs
and their corresponding BoEs were generally consistent and the MLE/BoE relationship maintained.
Switching to a lower yield cigarette generally resulted in reductions in exposure with the resultant expo-
sure level being similar to that seen in regular smokers of the lower yield cigarette.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The ability to estimate the exposure of smokers to cigarette
smoke constituents is critical for the assessment of changes in cig-
arette design aimed at reducing smokers’ exposure to cigarette
smoke.
Biomarkers of exposure (BoE) to smoke constituents have been
developed and used in a number of smoke exposure studies. These
include the measurement of the levels of nicotine in venous blood
(Russell et al., 1980, 1986; Ebert et al., 1983; Gori and Lynch, 1985),
cotinine in venous blood (Gori and Lynch, 1985; Bridges et al.,
1990; Rosa et al., 1992), cotinine in saliva (Jarvis et al., 2001) andTobacco, Group Research and
pton SO15 8TL, UK. Fax: +44
erd).
-NC-ND license.multiple nicotine metabolites in urine (Byrd et al., 1998; Ueda
et al., 2002). More recently studies have been conducted on the
measurement of BoE to cigarette smoke toxicants such as NNK
(4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) and pyrene
(Hecht et al., 2005; Benowitz et al., 2005; Scherer et al., 2007; Men-
des et al., 2008, 2009; Shepperd et al., 2009), benzene (Scherer
et al., 2006, 2007; Mendes et al., 2008), acrolein (Scherer et al.,
2006, 2007; Mendes et al., 2008; Shepperd et al., 2009), and 1,3-
butadiene (Scherer et al., 2006; Mendes et al., 2009). Most of the
biomarker studies rely on the measurements of metabolites of
the smoke constituent. Smokers may differ markedly in their
metabolism of smoke constituents. Additionally, the commonly
measured biomarkers have different elimination half-lives, some
relatively short e.g., nicotine, others relatively long e.g., NNAL (4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol) (metabolite for
NNK). Consequently, metabolism and half-life issues (where time
since exposure would affect biomarker level) may create problems
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lites in urine and saliva. However, problems caused by inter-sub-
ject variability in metabolism can be minimised by using each
subject as their own control during a cigarette brand-switch study.
Elimination half-life problems can be minimised by providing suf-
ﬁcient durations of biomarker monitoring during the smoking of
the pre- and post-switch cigarettes.
Another approach to estimating exposure to smoke constituents
is based on the analysis of spent cigarette ﬁlters. This method relies
on the measurement of the nicotine or solanesol content of the ﬁl-
ter after smoking, and the relationships between nicotine or
solanesol in the ﬁlter and the levels of smoke constituents in main-
stream smoke when the cigarette is smoked using a wide range of
machine-smoking regimes. From these two pieces of information it
is possible to estimate the amount of nicotine or other smoke con-
stituent that exited the ﬁlter and entered the smoker’s mouth –
Mouth Level Exposure (MLE). However, ﬁlter analysis methods
may be limited in their ability to predict exposures of smoke con-
stituents to, and absorption from, the respiratory tract as they do
not take account of non-inhaled puffs, ‘mouth-spill’ post-puff inha-
lation, exhalation patterns and differences in the respiratory reten-
tion of individual smoke constituents. Filter analysis methods have
previously been shown by a number of authors to provide good
estimates of MLE (St. Charles et al., 2006, 2010; Polzin et al.,
2009; Shepperd et al., 2006, 2009; Ashley et al., 2010). Recently,
in their review of cigarette ﬁlter based assays as proxies for smoke
exposure Pauly et al. (2009) concluded that ﬁlter based methods
may have utility as proxy measures of mouth level exposure in
clinical studies.
The ﬁndings presented in this manuscript extend those previ-
ously reported (Shepperd et al., 2009) which used data derived
from the same study. Our earlier paper focused on the primary
objective of the study, which was to compare smokers’ MLEs and
BoEs to speciﬁc cigarette smoke constituents as determined by
the use of both the ﬁlter analysis method (MLEs) and the analysis
of biomarkers of exposure in blood, urine and saliva (BoEs). We
demonstrated that these two exposure estimates were signiﬁ-
cantly correlated and we concluded that the measurement of MLEs
by ﬁlter analysis may provide a simple and effective alternative to
BoEs for estimating smokers’ exposure to smoke constituents. This
earlier paper (Shepperd et al., 2009) used data from the control
groups of smokers who smoked a brand of cigarette throughout
the study with the same or similar ISO tar yield as their usual cig-
arette (10, 4 or 1 mg ISO tar yield). However, this current report ad-
dresses the data from two additional groups of smokers who were
switched from their usual yield product (10 or 4 mg ISO tar) to a
lower ISO tar yield cigarette (4 or 1 mg ISO tar respectively) during
the study. This switching aspect was incorporated into the study
design in order to improve our understanding of the relationship
between MLEs and BoEs. The hypothesis underlying this approach
was that the switch from one ISO tar yield to a lower ISO tar yield
would change smoke exposure. Upsetting the equilibrium or stea-
dy state of smoke constituent exposure using an ISO tar yield
switch allows the direction and magnitude of the measured change
in exposure estimates from the two methods to be compared; if
there is a change in exposure as a result of switching, is the direc-
tion and magnitude of the change equally demonstrated by both
methods?
The data presented here, which includes the previously pub-
lished ﬁndings, allows both an examination of the inﬂuence of
ISO tar yield on estimated exposure (Shepperd et al., 2009) and
the effect of a switch to lower ISO yield on estimated exposure.
Whilst this was not the primary objective of the current study,
the inclusion of the control groups means that the study design
permits comparisons to be made that contribute to this discussion
on the relationship between ISO tar yield and exposure to cigarettesmoke constituents. In the previously reported aspects of this
study (Shepperd et al., 2009), smokers of lower yield cigarettes
generally had lower levels of MLE and biomarkers than those
smoking higher yield cigarettes. This second paper not only de-
scribes any changes in exposure that might occur following a
short-term switch to a lower ISO yield cigarette but it is also pos-
sible to compare levels of exposure seen in those smokers who did
not switch, or those who usually smoke the lower ISO yield
cigarette.
There have been a number of published studies on the effect of
switching from higher to lower ISO/FTC yield cigarettes on expo-
sure to nicotine (see Scherer, 1999). More recently there have been
a few brand-switching studies on the exposure to nicotine and
smoke toxicants such as NNK and pyrene (Benowitz et al., 2005,
2009; Mendes et al., 2008). Benowitz et al. (2005) reported small
reductions in blood cotinine and carboxyhaemoglobin levels ex-
pressed on a per cigarette basis but no changes in the levels of bio-
markers for NNK and pyrene when smokers switched from their
regular cigarette to one 50% lower in FTC nicotine yield for a period
of 1 week. A reduction in the levels of urinary nicotine metabolites
was also reported by Mendes et al. (2008) when smokers switched
from their regular to lower yield cigarettes in the short (8 days)
and long-term (24 weeks) phases of their study. However, in con-
trast to the results of Benowitz et al. (2005), Mendes et al. also re-
ported short and long-term reductions in the urinary biomarkers
for NNK and pyrene when smokers switched from a 15 to a 6 mg
FTC tar yield cigarette. In their more recent paper, Benowitz et al.
(2009) reported signiﬁcant reductions in the levels of cotinine in
plasma and NNAL and 2-naphthol in urine when smokers switched
from their usual brand (average yield of 1.05 mg nicotine) to a
0.1 mg nicotine yield brand. However, no signiﬁcant changes were
seen in these biomarkers when smokers switched from their usual
brand to a 0.6 mg nicotine yield brand. The switching aspect of our
study provides a source of additional information on the effect of
brand-switching on smokers exposure to smoke constituents such
as NNK, pyrene and acrolein.
2. Materials and methods
2.1. Study design
Three hundred healthy volunteers were recruited into the
study: 250 smokers and 50 non-smokers. The 250 smokers were
allocated to one of ﬁve groups according to the ISO tar yield of their
usual cigarette brand. Groups 1 and 2 each contained 50 smokers
of 9–10 mg ISO tar yield cigarettes; groups 3 and 4 each contained
50 smokers of 4–5 mg ISO tar yield cigarettes and group 5 con-
tained 50 smokers of 1–2 mg ISO tar yield cigarettes. The 50 non
smokers were assigned to group 6.
Three commercial brands of cigarettes were used for this study,
yielding nominally 10, 4 and 1 mg ISO tar thereby spanning the full
range of ISO tar yields legally available in Germany at the time of
the study. Smokers were supplied with cigarettes of the same to-
bacco blend style as their normal brand for the duration of the
study and all smokers began the study on a similar ISO tar and nic-
otine yield product to their usual brand. Although smokers were
required to change to a single brand at the start of the study, in
all cases the change was to a cigarette that was very similar in
all respects to their usual brand, and subjects were given 5 days
acclimatisation on the supplied cigarettes before baseline mea-
sures were taken. Any behavioural changes that may have re-
mained would not have inﬂuenced the objectives of this study
which were to determine whether the ﬁlter analysis and biomarker
methods would detect the same direction and magnitude of any
resultant change in exposure following a switch to a lower yield
cigarette.
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conducted by MDS Pharma Services, Hamburg, Germany. To ensure
compliance, all study samples (biological samples and spent ﬁlters)
were collected during the clinical periods only. Analyses of urinary
biomarkers were conducted by MDS Pharma Services laboratories
in Sittingbourne, UK and Zurich, Switzerland. Analyses of plasma
and saliva biomarkers were conducted by Analytisch Biologisches
Forschungslabor GmbH, Munich, Germany. Cigarette ﬁlters were
analysed by British American Tobacco, Group Research & Develop-
ment (BAT GR&D), Southampton, UK.
The study protocol and informed consent forms were approved
by the Ethics Committee of the Ärztekammer Hamburg and the
clinical study was conducted in accordance with the World Medi-
cal Association Declaration of Helsinki (World Medical Association
2004) and International Conference on Harmonisation (ICH)
Guidelines for Good Clinical Practice (GCP) (International Confer-
ence on Harmonisation 1996), current as at the date of the study.
Based on a recommendation by MDS Pharma Services, which was
endorsed by the ethics committee, it was agreed that subjects
would be paid a stipend of 1500 Euros for their participation in
the study.
2.1.1. Control groups
Three of the ﬁve smoker subject groups were control groups
who smoked a single brand for the entire study. Group 1 smoked
the 10 mg ISO tar yield cigarette, Group 3 smoked the 4 mg ISO
tar yield cigarette and Group 5 smoked the 1 mg ISO tar yield cig-
arette. The results from these three groups have been reported and
discussed previously (Shepperd et al., 2009). Some data from these
groups are included here where they serve as non-switching con-
trol groups and therefore provide a better understanding of any
changes that might occur in the two groups switching from higher
to lower ISO tar yield cigarettes.
2.1.2. Switching groups
The two remaining smoker groups began the study smoking the
supplied brand that was similar to their usual ISO tar and nicotine
yield. They were then switched to a lower ISO tar and ISO nicotine
yield cigarette for a period of 12 days. Group 2 started the study
smoking the 10 mg ISO tar yield cigarette before switching to the
4 mg ISO tar yield cigarette. Group 4 started the study smoking
the 4 mg ISO tar yield cigarette before switching to the 1 mg ISO
tar yield cigarette. These two groups of smokers are the main focus
of this paper.
The study design is summarised in Fig. 1. It includes both ambu-
latory and clinical conﬁnement periods. The ambulatory periods al-
lowed for acclimatisation to the product prior to clinical
conﬁnement and sample collection. The clinical periods were re-
quired to facilitate complete and accurate collection of 24 h urine
samples and ﬁlter tips from the smoked cigarettes. It also ensured
that subjects were compliant with the protocol in terms of diet and
cigarette consumption.
Full details of subject screening, ambulatory visit events and
clinical conﬁnement events are detailed by Shepperd et al. (2009).
The study design ensured that there were no mixed groups and
at any one time all subjects in the clinic who were smokers were
supplied with the same ISO tar yield cigarette. Potential confound-
ing effects were minimised or controlled as previously reported
(Shepperd et al., 2009) with the non smoker group providing mea-
sures of biomarkers that arise from non tobacco sources.
2.2. Product selection
Three commercial cigarette products were selected as previ-
ously described (Shepperd et al., 2009). The blend styles and key
physical parameters are shown in Table 1 together with themainstream smoke yields measured under both ISO (ISO 2000)
and Massachusetts Intense (Commonwealth of Massachusetts,
1997) regimes.
2.3. Subject selection
All subjects enrolled in this study were judged by the Principal
Investigator (PI) to be normal, healthy volunteers who met all
inclusion and none of the exclusion criteria as previously described
(Shepperd et al., 2009).
2.4. Methods
The methods used were as previously reported in detail by
Shepperd et al. (2009) including details on: – home smoking; ﬁlter
collection and analysis (including calibration for nicotine, NNK,
pyrene and acrolein MLE); urine collection and biomarker analy-
ses; saliva and plasma collection and analyses.
2.4.1. Home smoking
Smokers were supplied with cigarettes for home smoking dur-
ing the ambulatory sections of the study. The number of cigarettes
given to each subject was based on their claimed daily consump-
tion. Subjects were asked to record actual daily consumption dur-
ing ambulatory periods in a diary.
2.4.2. Filter collection and analysis
Smokers were permitted to smoke ad libitum throughout the
study which, in the clinic, was conﬁned to a designated room with
air ﬁltration systems installed. Smokers were issued with a ciga-
rette on request, with the next cigarette only supplied on receipt
of the spent cigarette ﬁlter, thus ensuring complete collection of
all ﬁlters in a 24 h period. On receipt, clinic staff cut a 10 mm sec-
tion from the mouth-end of the ﬁlter using a custom ﬁlter cutter.
This section was retained in an airtight aluminium tin which was
stored for up to 24 h at room temperature before being dispatched
by air freight to BAT for analysis. The times during which ﬁlters
were collected for analysis are indicated in Fig. 1.
MLEs to nicotine, NNK, pyrene and acrolein were estimated
using methods fully described by Shepperd et al. (2009). Brieﬂy,
the three cigarette types were calibrated by establishing the rela-
tionships between the amounts of nicotine retained in the ﬁlters
and the mainstream smoke yields of the relevant constituents dur-
ing machine smoking under a range of smoking regimes. The
amounts of nicotine retained in the ﬁlters of the cigarettes smoked
by the subjects were measured and MLEs for the four constituents
were determined using the calibration relationships for each con-
stituent and each cigarette type.
2.4.3. Urine collection and analysis
For all subjects 24 h urine samples were collected on the days
indicated in Fig. 1. The samples were analysed for total nicotine, to-
tal cotinine, and total trans-3-hydroxycotinine; total 4-(methylnit-
rosamino)-1-butanol (NNAL); hydroxypropyl mercapturic acid
(HPMA) and total 1-hydroxypyrene (1-OHP). ‘Total’ refers to the
sum of the free and conjugated forms of the biomarker. Full details
of the urine collection and analysis methods are shown in Shep-
perd et al. (2009).
2.4.4. Saliva and plasma collection and analyses
Saliva and blood samples were obtained from the subjects at
approximately 07:00 and 17:00 h on the days indicated in Fig. 1.
Full details of the sampling methods are contained in Shepperd
et al. (2009). The saliva and plasma samples were analysed for coti-
nine using the method described by Scherer et al. (2007).
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Table 1
Cigarette product details.
Group
1 and 2 2, 3 and 4 4 and 5
Subject chosen product
ISO tar, mg/cig 9–10 4–6 1–2
Blend style US US US
Format King size# King size# King size#
Supplied commercial product
Blend style US US US
Format King size# King size# King size#
Pack tar/nicotine/CO yields, mg/cig 10/0.8/10 4/0.4/5 1/0.1/2
ISO yields
Tar, mg/cig 10.5 4.7 1.0
Nicotine, mg/cig 0.83 0.45 0.12
CO, mg/cig 10.8 5.8 1.7
NNK, ng/cig 28.8 11.5 <LOQ*
Acrolein, lg/cig 45.3 27.3 7.3
Pyrene, ng/cig 49.4 33.0 11.2
Massachusetts yields
Tar, mg/cig 24.0 13.6 7.0
Nicotine, mg/cig 1.80 1.17 0.71
CO, mg/cig 22.3 15.5 11.2
NNK, ng/cig 65.6 33.6 19.7
Acrolein, lg/cig 108.0 77.2 53.1
Pyrene, ng/cig 105.3 72.2 43.0
Design
Filter ventilation, % 24 42 75
Paper permeability, CU 51 57 51
Total open pressure drop mmWG 100 101 86
CU – coresta units.
WG – water guage.
# King size approximate dimensions; length 83 mm, circumference 24.75 mm,
ﬁlter length 27 mm.
* <LOQ – less than the limit of quantitation for NNK (8 ng/cig).
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Minitab (version 15, Minitab Ltd., UK) was used for statistical
analyses. For each subject a mean of the results for each period
were used (i.e. a mean of day 6 and day 7 results for period 1
and a mean of day 18 and day 19 results for period 2) in theanalyses for both MLEs and BoEs . The cigarettes per day, MLE
and BoEs results expressed both per cigarette and per day were
summarised by group and period using Minitab’s descriptive sta-
tistics. Checks for normality were carried out, using normality plots
and standardised residuals, before comparison between periods for
each group was made using paired t-tests with Bonferroni
correction.
Modiﬁed, combined ‘box plots’ were constructed to show the
relationship between control group results and switching group re-
sults. They combined the ﬁrst and third quartile results plus the
mean for each relevant MLE/biomarker pair in a two dimensional
plot with MLE on the x-axis and biomarker on the y-axis. Separate
boxes represent each group/period demonstrating the relationship
between the relevant biomarker and constituent MLE. The use of
boxes gives a representation of the spread of data within each
group/period.
The mean daily cigarette consumption rates, MLEs and BoEs for
period 1 and 2 for the switching groups were compared with those
for their corresponding non-switching, control groups using a two
sample t-test with unequal variances.
The relationship between MLE, as determined by ﬁlter analysis,
and the relevant BoE was assessed by linear regression.
3. Results
A total of 300 subjects were recruited for this study. Results
from 280 subjects (47 in group 1, 46 in group 2, 45 in group 3,
44 in group 4, 48 in group 5 and 50 in group 6) were used in the
ﬁnal data analysis. Data from subjects not used were for 6 subjects
who chose to withdraw from the study, 3 subjects who were re-
moved for violating protocol, 2 subjects who were withdrawn from
the study due to serious adverse events and data from 9 subjects
who completed the study but were excluded due to errors in sam-
ple collection.
Subject demographics and self-reported smoking habits are
shown in Table 2.
The mean and 95% conﬁdence interval (CI) results obtained for
the MLEs per day and BoEs, along with cigarette consumption are
summarised in Table 3 by group and by period. A paired t-test with
Bonferroni correction was used to compare results between
Table 2
Demographics and self-reported smoking habit.
Group No. subjects Gender Age Cigs per day Pack nicotine (mg/cig) Pack tar (mg/cig)
n (% male) Mean (min–max) Mean (min–max) Median (min–max) Median (min–max)
1 47 68 42 (22–72) 21 (14–30) 0.8 (0.7–0.9) 10.0 (10.0–10.0)
2 46 63 33 (21–60) 21 (14–30) 0.8 (0.7–0.9) 10.0 (9.0–10.0)
3 45 44 36 (21–66) 20 (14–30) 0.5 (0.4–0.6) 6.0 (4.0–6.0)
4 44 34 35 (21–59) 20 (6–30) 0.6 (0.4–0.6) 6.0 (4.0–6.0)
5 49 37 37 (22–70) 18 (8–30) 0.1 (0.1–0.2) 1.0 (1.0–2.0)
6 50 62 44 (22–74) 0 n/a n/a
Means shown for age and cigs per day (cigarettes per day) since continuous variables.
Medians shown for pack nicotine and pack tar since categorical variables.
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in this table. Since there were 12 comparisons (i.e. nicotine, NNK,
acrolein and pyrene MLE, plus the urinary biomarkers, plus 2 plas-
ma and 2 saliva cotinine measures) then the Bonferonni correction
for the p value for signiﬁcance was 0.05/12 = 0.004 and therefore
comparisons with p values > 0.004 were not signiﬁcant.
Mean daily cigarette consumption was higher in period 2 than
in period 1 for all ﬁve smoker groups. Closer examination of ciga-
rette consumption in the clinic identiﬁed a systematic increaseTable 3
Mean (95% CI) Mouth Level Exposure (MLE), biomarkers of exposure (BoE) and cigarette c
Group N Period 1 Period 2 p
Cigarettes per day
1 47 21.1 (19.6, 22.6) 23.8 (22.3, 25.2) 0
2 46 21.8 (20.4, 23.1) 25.3 (23.1, 27.5) 0
3 45 19.8 (18.1, 21.5) 23.2 (21.3, 25.1) 0
4 44 18.5 (17.2, 19.8) 22.3 (20.6, 24.0) 0
5 48 18.5 (16.4, 20.6) 20.1 (18.1, 22.1) 0
Nicotine MLE, mg/day
1 47 30.8 (27.5, 34.1) 34.4 (31.1, 37.7) 0
2 46 29.1 (26.3, 31.9) 23.9 (21.3, 26.4) 0
3 45 19.1 (17.0, 21.3) 23.6 (20.9, 26.4) 0
4 44 18.4 (16.5, 20.3) 19.9 (17.2, 22.6) 0
5 48 15.2 (12.7, 17.8) 16.7 (14.3, 19.1) 0
NNK MLE, ng/day
1 47 1112 (989, 1235) 1241 (1119, 1363) 0
2 46 1045 (942, 1149) 673 (599, 747) 0
3 45 540 (476, 603) 671 (590, 752) 0
4 44 522 (467, 578) 529 (464, 594) 0
5 48 411 (348, 473) 450 (390, 509) 0
Acrolein MLE, lg/day
1 47 1815 (1610, 2020) 2025 (1822, 2228) 0
2 46 1699 (1526, 1871) 1553 (1383, 1722) 0
3 45 1245 (1100, 1389) 1544 (1360, 1729) 0
4 44 1204 (1076, 1331) 1503 (1294, 1712) 0
5 48 1147 (954, 1340) 1259 (1076, 1442) 0
Pyrene MLE, ng/day
1 47 1809 (1615, 2002) 2020 (1828, 2211) 0
2 46 1711 (1548, 1874) 1512 (1358, 1666) 0
3 45 1207 (1078, 1337) 1482 (1318, 1645) 0
4 44 1160 (1047, 1272) 1180 (1027, 1333) 0
5 48 910 (765, 1054) 997 (860, 1135) 0
Plasma cotinine 0700 h, ng/ml
1 47 262 (233, 291) 275 (250, 301) 0
2 46 244 (212, 276) 233 (205, 261) 0
3 45 169 (143, 194) 192 (166, 218) 0
4 44 172 (151, 193) 159 (138, 180) 0
5 48 130 (109, 151) 138 (115, 160) 0
Saliva cotinine 0700 h, ng/ml
1 47 323 (280, 366) 327 (287, 368) 0
2 46 273 (228, 319) 283 (242, 325) 0
3 45 168 (140, 195) 206 (176, 236) 0
4 43a 167 (144, 190) 180 (152, 208) 0
5 48b 136 (108, 164) 157 (128, 185) 0
a Saliva 1700 h p1 N = 44.
b Saliva 0700 h p1 N = 47.across the study over time, particularly for the last clinic day
(day 19) where 87% of subjects showed increased cigarette con-
sumption compared with baseline (day 6). Fig. 2 shows the mean
cigarette consumption per day for each group and demonstrates
this systematic observation of increasing cigarette consumption
across the study for all groups.
It is unlikely that this trend in increased consumption as the
study progressed occurred as a consequence of the switch from
higher to lower yield cigarettes because increased consumptiononsumption by group expressed as amount per day.
-Value Period 1 Period 2 p-Value
.000
.000
.000
.000
.001
TNeq, mg/day
.000 18.0 (15.8, 20.1) 18.3 (16.4, 20.2) 0.412
.000 16.9 (14.3, 19.4) 15.8 (13.7, 17.9) 0.077
.000 12.4 (10.7, 14.1) 14.4 (12.2, 16.5) 0.000
.032 11.8 (10.2, 13.4) 9.5 (8.1, 10.8) 0.000
.002 7.1 (5.9, 8.3) 8.3 (7.0, 9.6) 0.001
NNAL, ng/day
.000 491 (426, 555) 487 (424, 549) 0.682
.000 437 (348, 526) 337 (282, 391) 0.000
.000 282 (238, 325) 308 (254, 363) 0.006
.693 266 (228, 304) 259 (209, 309) 0.569
.001 179 (147, 211) 212 (178,245) 0.000
3-HPMA, jg/day
.000 2007 (1732, 2282) 2050 (1780, 2320) 0.398
.001 1789 (1502, 2076) 1991 (1654, 2329) 0.002
.000 1256 (1060, 1452) 1451 (1194, 1708) 0.001
.000 1367 (1145, 1590) 1119 (916, 1323) 0.000
.002 880 (717, 1043) 988 (816, 1160) 0.007
1-OHP, ng/day
.000 335 (286, 384) 326 (285, 367) 0.327
.000 303 (256, 351) 292 (250, 334) 0.314
.000 254 (223, 284) 271 (233, 309) 0.072
.597 231 (201, 261) 185 (162, 209) 0.000
.002 147 (129, 165) 164 (145, 184) 0.017
Plasma cotinine 1700 h, ng/ml
.043 269 (241, 297) 290 (265, 315) 0.000
.094 260 (229, 290) 247 (219, 276) 0.044
.000 181 (156, 207) 204 (178, 229) 0.000
.029 188 (166, 210) 168 (145, 191) 0.001
.088 134 (113, 155) 142 (119, 164) 0.033
Saliva cotinine 1700 h, ng/ml
.881 342 (293, 391) 371 (335, 407) 0.099
.748 338 (292, 384) 334 (289, 379) 0.711
.073 215 (184, 246) 264 (226, 302) 0.000
.470 224 (194, 254) 222 (189, 254) 0.964
.315 160 (134, 187) 180 (150, 210) 0.001
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Fig. 2. Daily cigarette consumption by group and day.
Table 5
A comparison of mean daily exposure data for group 4 (4–1 mg switchers) relative to
group 3 (4 mg control group) before (period 1) and after switching (period 2).
Period 1 (%) Period 2 (%)
Cig consumption 6.6 3.8
Nicotine MLE 3.5 15.7
TNeq 4.8 34.1***
Plasma cotinine 0700 +2.2 17.0
Plasma cotinine 1700 +3.7 17.5*
Saliva cotinine 0700 0.7 12.5
Saliva cotinine 1700 +4.2 16.2
NNK MLE 3.2 21.2**
NNAL 5.6 16.0
Acrolein MLE 3.3 2.7
3-HPMA +8.8 22.9*
Pyrene MLE 3.9 20.4**
1-OHP 8.9 31.6***
Note: Group 4 mean values expressed as a % of group 3 mean values.
* p < 0.05 for comparison of group 3 and 4 mean values – two sample t-test
(unequal variances).
** p < 0.01 for comparison of group 3 and 4 mean values – two sample t-test
(unequal variances).
*** p < 0.001 for comparison of group 3 and 4 mean values – two sample t-test
(unequal variances).
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this increase was due to the subjects becoming more at ease with
the experimental procedures as the study progressed. Although not
reported, a similar level of increase in cigarette consumption
on the last day was seen in a previous clinical study with a simi-
lar experimental design (St. Charles et al., 2006; personal
communication).
One data analysis approach to minimising the possible effect of
the experimental conditions causing an increase in daily cigarette
consumption from the start to the end of the study, thereby inﬂu-
encing the mean exposure per day data, is to express mean expo-
sure per day data for the switching groups relative to the
appropriate control groups for periods 1 and 2 of the study. The
daily exposures for group 2 relative to group 1 are show in Table
4, and those for group 4 relative to group 3 are shown in Table 5.
During period 1 both the control (group 1) and switching group
(group 2) smoked the 10 mg tar yield product. The mean daily
exposure levels were marginally lower for group 2 than for group
1 during this period. However, none of these differences were sta-
tistically signiﬁcant (p > 0.05 for all comparisons). Switching from
the 10 to the 4 mg product resulted in mean values for group 2
being considerably lower than those for group 1 for most of the
exposure parameters. These differences were statistically signiﬁ-
cant for nicotine, NNK, acrolein and pyrene MLEs (p < 0.001 in allTable 4
A comparison of mean daily exposure data for group 2 (10–4 mg switchers) relative to
group 1 (10 mg control group) before (period 1) and after switching (period 2).
Period 1 (%) Period 2 (%)
Cig consumption +3.0 +6.2
Nicotine MLE 5.6 30.6***
TNeq 6.1 13.5
Plasma cotinine 0700 6.8 15.3*
Plasma cotinine 1700 3.5 14.8*
Saliva cotinine 0700 15.3 13.4
Saliva cotinine 1700 1.2 9.9
NNK MLE 6.0 45.8***
NNAL 11.0 30.8***
Acrolein MLE 6.4 23.3***
3-HPMA 10.8 2.9
Pyrene MLE 5.4 25.1***
1-OHP 9.5 10.5
Note: Group 2 mean values expressed as a % of group 1 mean values.
* p < 0.05 for comparison of group 1 and 2 mean values – two sample t-test
(unequal variances).
*** p < 0.001 for comparison of group 1 and 2 mean values – two sample t-test
(unequal variances).cases), total NNAL (p < 0.001) and both measures of plasma coti-
nine (p < 0.05 for both).
A similar pattern to the one described above was observed
when the group 4 (switchers from 4 to 1 mg product) and group
3 (4 mg control group) mean daily exposure data were compared
(Table 5). There were marginal and statistically insigniﬁcant differ-
ences (p > 0.05 for all comparisons) in the MLEs and BoEs between
the two groups during period 1 when both groups smoked the
4 mg product. However, in period 2 the mean MLEs and BoEs for
the switchers were consistently lower that of the control group
except for acrolein MLE. These differences were statistically signif-
icant for NNK and pyrene MLEs (p < 0.01 for both), TNeq and 1-OHP
(p < 0.001 for both), 3-HPMA and plasma cotinine 1700 h (p < 0.05
for both). The difference in nicotine MLE just failed to reach signif-
icance at the 95% level.
The exposure data can also be expressed on a per cigarette ba-
sis. The MLE data were initially measured on a per cigarette basis
and were converted to MLE per day by multiplying with daily cig-
arette consumption. However, the urinary biomarker data reﬂect
daily exposure. Hence exposure per cigarette values were obtained
by simply dividing the BoE values by the corresponding cigarette
consumption value. The exposure per cigarette data are summa-
rised in Table 6 and paired t-tests with Bonferroni correction used
to provide p values. Again, as with Table 3, p < 0.004 are required to
indicate a signiﬁcant difference.
Comparing MLE estimates for periods 1 and 2, there were no
signiﬁcant differences (p > 0.004) for the control groups 1 and 5
while control group 3 showed barely signiﬁcant increases (p =
0.003) for nicotine, NNK, acrolein and pyrene. Signiﬁcant reduc-
tions in levels of BoEs were found for the 10 mg control group
(group 1) for TNeq, NNAL, 3-HPMA and 1-OHP but no change in
plasma or saliva cotinine. There were no signiﬁcant differences in
any BoEs for either of the other two control groups.
In contrast, switching from the 10 to the 4 mg cigarette (i.e.
group 2) produced signiﬁcant reductions in all MLEs per cigarette
for nicotine, NNK, acrolein and pyrene. There were also signiﬁcant
reductions in the levels of BoEs per cigarette for TNeq, NNAL, 1-
OHP, plasma cotinine, and saliva cotinine 1700 h. There were no
signiﬁcant changes in the levels of 3-HPMA or saliva cotinine
0700 h.
Switching from the 4 to the 1 mg cigarette (i.e. group 4) pro-
duced statistically signiﬁcant reductions in all the measured MLEs
per cigarette except acrolein MLE. Signiﬁcant reductions following
Table 6
Mean (95% CI) Mouth Level Exposure (MLE) and Biomarkers of exposure (BoE) by group and period expressed as amount per cigarette.
Group N Period 1 Period 2 p-Value Period 1 Period 2 p-Value
Nicotine MLE, mg/cig TNeq, mg/cig
1 47 1.44 (1.35, 1.54) 1.44 (1.35, 1.52) 0.537 0.84 (0.76, 0.92) 0.77 (0.71, 0.84) 0.002
2 46 1.33 (1.24, 1.41) 0.94 (0.89, 1.00) 0.000 0.76 (0.66, 0.85) 0.62 (0.56, 0.68) 0.000
3 45 0.95 (0.88, 1.03) 1.00 (0.92, 1.08) 0.003 0.62 (0.54, 0.69) 0.60 (0.54, 0.66) 0.301
4 44 0.98 (0.92, 1.04) 0.88 (0.80, 0.95) 0.000 0.62 (0.56, 0.69) 0.42 (0.37, 0.46) 0.000
5 48 0.80 (0.73, 0.86) 0.81 (0.74, 0.87) 0.509 0.38 (0.33, 0.43) 0.41 (0.36, 0.45) 0.272
NNK MLE, ng/cig NNAL, ng/cig
1 47 52.1 (48.6, 55.6) 51.8 (48.5, 55.0) 0.537 22.9 (20.6, 25.2) 20.3 (18.2, 22.3) 0.000
2 46 47.7 (44.5, 50.8) 26.6 (24.8, 28.3) 0.000 19.8 (16.0, 23.6) 13.3 (11.6, 15.0) 0.000
3 45 26.9 (24.5, 29.2) 28.4 (25.9, 30.8) 0.003 14.0 (12.1, 16.0) 12.8 (11.1, 14.5) 0.007
4 44 27.7 (25.9, 29.5) 23.3 (21.6, 25.0) 0.000 14.0 (12.4, 15.6) 11.3 (9.7, 12.9) 0.000
5 48 21.6 (20.1, 23.1) 21.8 (20.4, 23.3) 0.509 9.7 (8.1, 11.3) 10.5 (9.2, 11.8) 0.158
Acrolein MLE, lg/cig 3-HPMA, lg/cig
1 47 85.0 (79.0, 91.0) 84.5 (78.9, 90.0) 0.537 92.6 (83.3, 101.9) 85.4 (76.3, 94.5) 0.003
2 46 77.4 (72.0, 82.8) 61.3 (57.4, 65.2) 0.000 80.0 (69.3, 90.6) 76.2 (67.7, 84.8) 0.047
3 45 62.0 (56.7, 67.2) 65.3 (59.8, 70.9) 0.003 62.5 (54.3, 70.6) 59.3 (51.8, 66.8) 0.090
4 44 63.9 (59.7, 68.0) 66.0 (60.1, 71.9) 0.181 71.4 (62.5, 80.3) 48.6 (42.2, 55.0) 0.000
5 48 59.9 (54.7, 65.2) 60.7 (55.5, 65.8) 0.509 46.4 (40.6, 52.1) 47.4 (41.6, 53.1) 0.630
Pyrene MLE, ng/cig 1-OHP, ng/cig
1 47 84.8 (79.4, 90.2) 84.3 (79.4, 89.3) 0.537 15.6 (13.8, 17.3) 13.8 (12.3, 15.3) 0.000
2 46 78.0 (73.2, 82.8) 59.8 (56.7, 62.8) 0.000 13.7 (11.8, 15.6) 11.6 (10.3, 12.9) 0.000
3 45 60.3 (56.1, 64.4) 62.9 (58.5, 67.3) 0.003 13.3 (11.5, 15.0) 11.8 (10.6, 13.0) 0.003
4 44 61.7 (58.5, 65.0) 51.9 (47.8, 56.0) 0.000 12.5 (11.2, 13.8) 8.4 (7.5, 9.2) 0.000
5 48 47.7 (44.1, 51.4) 48.3 (44.7, 51.8) 0.509 8.5 (7.5, 9.5) 8.6 (7.6, 9.6) 0.877
Plasma cotinine 0700 h, ng/ml/cig Plasma cotinine 1700 h, ng/ml/cig
1 47 12.4 (11.4, 13.5) 11.7 (10.7, 12.8) 0.032 12.8 (11.8, 13.8) 12.4 (11.4, 13.4) 0.184
2 46 11.1 (9.8, 12.4) 9.3 (8.4, 10.3) 0.000 11.8 (10.6, 13.0) 9.9 (9.0, 10.8) 0.000
3 45 8.6 (7.3, 9.9) 8.4 (7.3, 9.5) 0.509 9.1 (7.9, 10.3) 8.9 (7.8, 10.0) 0.248
4 44 9.3 (8.3, 10.2) 7.2 (6.3, 8.0) 0.000 10.1 (9.1, 11.0) 7.5 (6.7, 8.3) 0.000
5 48 6.9 (6.1, 7.7) 6.8 (5.8, 7.8) 0.552 7.1 (6.4, 7.8) 6.9 (6.1, 7.7) 0.317
Saliva cotinine 0700 h, ng/ml/cig Saliva cotinine 1700 h, ng/ml/cig
1 47 15.2 (13.5, 16.9) 13.8 (12.3, 15.3) 0.021 16.0 (14.2, 17.7) 15.9 (14.4, 17.4) 0.786
2 46 12.3 (10.5, 14.1) 11.2 (9.8, 12.6) 0.009 15.3 (13.5, 17.1) 13.2 (11.7, 14.7) 0.000
3 45 8.4 (7.0, 9.7) 9.0 (7.7, 10.2) 0.194 10.8 (9.3, 12.2) 11.5 (10.0, 13.0) 0.052
4 43a 8.9 (7.8, 10.0) 8.1 (7.0, 9.1) 0.009 11.9 (10.5, 13.4) 9.9 (8.6, 11.1) 0.000
5 48b 7.0 (5.9, 8.1) 7.6 (6.4, 8.8) 0.032 8.4 (7.5, 9.3) 8.8 (7.7, 9.9) 0.221
a Saliva 1700 h p1 N = 44.
b Saliva 0700 h p1 N = 47.
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BoEs per cigarette except salivary cotinine 0700 h.
The effects of switching brand on both MLE and BoE results per
cigarette are also shown in Fig. 3, where modiﬁed, 2-dimensional,
box plots show the boundaries of the central 50% of data and the
median for each group/period combining relevant MLE and urinary
BoE pairs.
The nicotine MLE and nicotine biomarker data from groups 2
and 4 were used to determine the degrees of compensation that
occurred following the switch from higher to lower ISO yield ciga-
rettes. The following equation was used to determine the compen-
sation index (CIx) (from Scherer, 1999):
CIx ¼ 1  ½ð% changeinexposuremarkerfornicotineÞ
=ð% changeinnicotineISOyieldÞ
Nicotine MLE, TNeq, plasma and saliva cotinine values were
used as nicotine exposure markers and % changes in ISO nicotine
yields of 45.8% (group 2) and 73.3% (group 4) were used to de-
rive the CIx values shown in Table 7.
The calculated CIx values were less than one but greater than
zero in each case indicating partial compensation following the
brand switches in both groups 2 and 4. The degree of partial
compensation differed according to the nicotine exposure marker
used in the calculations. For the biomarkers of nicotine exposure,
saliva cotinine produced the highest CIx value in both groups. Nic-
otine MLE produced a CIx that was lower than those calculatedusing the biomarkers of nicotine exposure for the group 2 smokers.
However, this was not the case for the group 4 smokers as nicotine
MLE produced a higher CIx than the biomarkers of nicotine
exposure.
Previously (Shepperd et al., 2009) a regression analysis was used
to assess the correlation between BoE andMLE. The results of a sim-
ilar analysis of the per cigarette results comparing control groups to
switching groups and splitting the switching groups into pre-switch
(period 1) and post-switch (period 2) are shown in Table 8.
The regression analysis again shows strong positive linear rela-
tionships across all comparisons for control groups and switching
groups, both pre and post-switch, with p < 0.001 for slope in all
cases. The slopes and intercepts are similar comparing the same
MLE/biomarker pairs with the slope and conﬁdence interval for
the control groups falling within the conﬁdence interval for the
switching results. The Pearson correlation coefﬁcient, r, is also sim-
ilar between control and switching groups for the relevant pairs.
The only exception to this is the 3-HPMA/acrolein MLE pair where
the intercept post-switch has decreased such that the 95% conﬁ-
dence intervals for the mean control group slope does not lie en-
tirely within the interval for the post-switching results.
A key aspect of the study design is that subjects in groups 2 and
4 can be used as their own control by comparing directional
changes in their MLEs with those of their corresponding BoEs fol-
lowing the switch from higher to lower yield cigarettes.
Table 9 summarises the directional changes in each MLE and
BoE pair following the switch from higher to lower yield cigarettes
in groups 2 and 4.
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Fig. 3. Modiﬁed boxplots showing urinary biomarker versus Mouth Level Exposure (MLE). Key: 10 mg ISO tar cigarettes, 4 mg ISO tar cigarettes, 1 mg ISO tar cigarettes. Solid
line period 1 data, dotted line period 2 data. Left and right box sides – 1st and 3rd quartile for MLE. Bottom and top box sides – 1st and 3rd quartile for biomarker: x – median
value for period 1 data. + median value for period 2 data. Section A shows group 2 data, B shows control groups 1, 3 and 5 data, and C shows group 4 data.
Table 7
Compensation indices following the switch from the 10 to the 4 mg cigarette (group
2) and 4 to 1 mg cigarette (group 4).
Parameter Group 2 Group 4
Nicotine MLE 0.38 0.84
TNeq 0.74 0.56
Plasma cotinine 0700 0.66 0.69
Plasma cotinine 1700 0.66 0.64
Saliva cotinine 0700 0.90 0.82
Saliva cotinine 1700 0.79 0.74
S20 C.J. Shepperd et al. / Regulatory Toxicology and Pharmacology 61 (2011) S13–S24It can be seen from Table 9 that there are good agreements
(70–94%) between the directional changes for MLEs and BoEs for
nicotine, NNK and pyrene. However, this was not the case for acro-
lein as only 52% (group 2) and 50% (group 4) of the smokers
showed consistent directional changes in both indices of acrolein
exposure.4. Discussion
The availability of methods for quantifying exposure to ciga-
rette smoke constituents is a necessary requirement for the initial
phase of an assessment of cigarette-based potential reduced-expo-
sure products (PREPS) (Institute of Medicine 2001).
In a previous paper (Shepperd et al., 2009), we compare two ap-
proaches to the estimation of cigarette smoke exposure in a cross-
sectional study of three groups of smokers who differed in the ISO
tar and nicotine yields of their usual cigarette brands. One ap-
proach was the measurement of MLEs using the ﬁlter analysis
method, and the other was the measurement of BoE. We reported
moderate to strong correlations for nicotine MLE and urinary TNeq
(r = 0.83), NNK MLE and NNAL (r = 0.76), acrolein MLE and 3-HPMA
(r = 0.82), and pyreneMLE and 1-OHP (r = 0.63). These data also de-
rive from the control groups from this current study. It should be
noted that in the earlier reported analysis, mean MLE and BoE val-
ues were calculated from all days for each subject, giving rise to a
reduced n and slight differences in the values shown.
Table 8
Linear regression analysis data (per cigarette results).
Comparison n Slope (95% CI) Slope SE Intercept (95% CI) Intercept SE r
Control groups
TNeq versus nicotine MLE 280 0.52 (0.46–0.58) 0.03 0.04 (0.03 to 0.11) 0.03 0.71
NNAL versus NNK MLE 280 0.33 (0.28–0.37) 0.02 4.0 (2.2–5.7) 0.9 0.64
3-HPMA versus acrolein MLE 280 0.99 (0.87–1.12) 0.06 3.6 (12.9 to 5.7) 4.7 0.68
1-OHP versus pyrene MLE 280 0.10 (0.08–0.13) 0.01 5.2 (3.3–7.1) 1.0 0.40
Plasma cotinine 0700 h versus nicotine MLE 280 7.0 (6.0–8.0) 0.5 1.6 (0.4–2.8) 0.6 0.62
Plasma cotinine 1700 h versus nicotine MLE 280 7.3 (6.4–8.2) 0.5 1.7 (0.6–2.7) 0.5 0.69
Salivary cotinine 0700 h versus nicotine MLE 279# 9.1 (7.7–10.4) 0.7 0.4 (1.1 to 2.0) 0.8 0.61
Salivary cotinine 1700 h versus nicotine MLE 280 9.4 (8.0–10.8) 0.7 1.8 (0.2–3.3) 0.8 0.63
Switching groups – pre-switch
TNeq versus nicotine MLE 90 0.58 (0.43–0.74) 0.08 0.01 (0.17 to 0.20) 0.09 0.62
NNAL versuss NNK MLE 90 0.38 (0.24–0.53) 0.07 2.4 (3.5 to 8.2) 2.9 0.48
NNAL versus NNK MLE (less 1 outlier) 89 0.28 (0.18–0.37) 0.05 5.7 (2.0–9.4) 1.9 0.53
3-HPMA versus acrolein MLE 90 1.17 (0.85–1.48) 0.16 6.8 (30.0 to 16.3) 11.7 0.61
1-OHP versus pyrene MLE 90 0.15 (0.09–0.22) 0.03 2.5 (2.2 to 7.1) 2.3 0.43
1-OHP versus pyrene MLE (less 1 outlier) 89 0.12 (0.06–0.17) 0.03 4.6 (0.5–8.6) 2.0 0.40
Plasma cotinine 0700 h versus nicotine MLE 90 7.0 (4.5–9.4) 1.2 2.1 (0.8 to 5.0) 1.5 0.51
Plasma cotinine 1700 h versus nicotine MLE 90 7.3 (5.2–9.5) 1.1 2.5 (0.1 to 5.1) 1.3 0.58
Salivary cotinine 0700 h versus nicotine MLE 89# 10.1 (7.0–13.2) 1.6 1.0 (4.7 to 2.7) 1.9 0.57
Salivary cotinine 0700 h versus nicotine MLE (less 1 outlier) 88 8.9 (6.2–11.7) 1.4 0.1 (3.2 to 3.4) 1.7 0.56
Salivary cotinine 1700 h versus nicotine MLE 90 11.3 (8.0–14.5) 1.6 0.6 (3.3 to 4.5) 2.0 0.59
Switching groups – post-switch
TNeq versus nicotine MLE 90 0.54 (0.39–0.68) 0.07 0.03 (0.11 to 0.17) 0.07 0.61
NNAL versus NNK MLE 90 0.47 (0.29–0.64) 0.09 0.7 (3.9 to 5.2) 2.3 0.48
NNAL versus NNK MLE (less 2 outliers) 88 0.39 (0.25–0.53) 0.07 2.2 (1.4 to 5.7) 1.8 0.50
3-HPMA versus acrolein MLE 90 0.72 (0.39–1.05) 0.17 16.9 (4.9 to 38.6) 11.0 0.41
1-OHP versus pyrene MLE 90 0.16 (0.10–0.22) 0.03 0.9 (2.5 to 4.3) 1.7 0.50
1-OHP versus pyrene MLE (less 1 outlier) 89 0.14 (0.08–0.19) 0.03 2.3 (0.9 to 5.5) 1.6 0.45
Plasma cotinine 0700 h versus nicotine MLE 90 6.2 (3.4–8.9) 1.4 2.7 (0.1–5.2) 1.3 0.42
Plasma cotinine 1700 h versus nicotine MLE 90 7.2 (4.6–9.7) 1.3 2.2 (0.2 to 4.6) 1.2 0.50
Salivary cotinine 0700 h versus nicotine MLE 89# 9.3 (5.6–13.0) 1.9 1.2 (2.2 to 4.7) 1.7 0.46
Salivary cotinine 1700 h versus nicotine MLE 89# 11.4 (7.6–15.3) 1.9 1.2(2.4 to 4.8) 1.8 0.53
All groups
TNeq versus nicotine MLE 460 0.54 (0.49–0.59) 0.03 0.03 (0.02 to 0.09) 0.03 0.70
NNAL versus NNK MLE 460 0.34 (0.30–0.39) 0.02 3.6 (2.1–5.1) 0.8 0.60
3-HPMA versus acrolein MLE 460 0.98 (0.87–1.1) 0.06 0.5 (8.7 to 7.6) 4.1 0.62
1-OHP versus pyrene MLE 459# 0.12 (0.09–0.14) 0.01 4.3 (2.9–5.8) 0.7 0.43
Plasma cotinine 0700 h versus nicotine MLE 460 7.0 (6.1–7.8) 0.4 1.8 (0.9–2.8) 0.5 0.59
Plasma cotinine 1700 h versus nicotine MLE 460 7.4 (6.6–8.2) 0.4 1.9 (1.0–2.7) 0.4 0.66
Salivary cotinine 0700 h versus nicotine MLE 457### 9.0 (7.8–10.1) 0.6 0.7 (0.6 to 2.0) 0.6 0.58
Salivary cotinine 1700 h versus nicotine MLE 459# 9.7 (8.5–10.9) 0.6 1.9 (0.6–3.2) 0.7 0.61
CI = conﬁdence interval.
SE = standard error.
Outliers identiﬁed where standardised residual is >3.6.
# 1 Sample mising.
### 3 Sample missing.
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not the relationships between estimates of MLEs and their appro-
priate BoEs were maintained when smokers were switched from
their usual brand to one of a lower machine-derived smoke yield.
Using a single supplied product at each tar yield, rather than
allowing individuals to source and smoke their own brands
empowered the switching aspect of this study. A variety of subject
sourced brands within each group would have made it difﬁcult to
control and initiate the same level of potential change for each
subject. Since the objectives of this study were best served if a
measurable change in smoke exposure was seen following the
switch, it was also important that the cigarette brands used pre-
and post-switch were signiﬁcantly different, in terms of ISO yield.
The previously reported results from the control groups indicated
that both methods could detect a signiﬁcant difference in the levels
of exposure from the three ISO tar yield cigarettes and that the dif-
ferences were in line with the ISO tar yield of the cigarettes
smoked (Shepperd et al., 2009). In addition, using only three ciga-
rette brands also offered several technical advantages, as previ-
ously reported (Shepperd et al., 2009).MLE provides a measure of the amount of smoke constituent
leaving the cigarette and entering the mouth during the puff pro-
cess. However, factors such as possible changes in the degree of
mouthspill (smoke exiting the mouth prior to post-puff inhalation)
and post-puff inhalation/exhalation depths and durations follow-
ing the brand-switch may disrupt the relationships between MLEs
and BoEs. A change in post-puff inhalation depth and duration
should only inﬂuence these relationships for those constituents
whose respiratory deposition and retention characteristics are
modiﬁed by changes in post-puff respiratory patterns. Of the con-
stituents measured in the current study only the respiratory reten-
tion of NNK appears to be inﬂuenced by changes in post-puff
respiratory patterns (Feng et al., 2007). Studies have shown that
nicotine is very highly retained within the respiratory tract (Armit-
age et al., 1975, 2004; Baker and Dixon, 2006; Feng et al., 2007),
and its degree of retention is not markedly inﬂuenced by changes
in post-puff inhalation depth and duration (Zacny et al., 1987;
Armitage et al., 2004; Baker and Dixon, 2006; Feng et al., 2007).
As both acrolein (Moldoveanu et al., 2007) and pyrene (Moldov-
eanu et al., 2008) are also very highly retained in the respiratory
Table 9
Percentage of subjects where direction of change in exposure agree or disagree between methods.
Comparison Group  (%) +/+ (%) ++ (%) Total in agreement (%)
Nicotine MLE/TNeq 2 83 17 0 83
4 73 23 5 77
Nicotine MLE/plasma cotinine 1700 2 85 15 0 85
4 73 27 0 73
Nicotine MLE/saliva cotinine 1700 2 70 30 0 70
4 65 21 14 79
NNK MLE/NNAL 2 94 7 0 94
4 64 30 7 77
Acrolein MLE/3-HPMA 2 50 48 2 52
4 48 50 2 50
Pyrene MLE/1-OHP 2 76 24 0 76
4 75 25 0 75
Key: Denotes a decrease in both MLE and BoE; ++ denotes an increase in both MLE and BoE;+/+ denotes a either a decrease in MLE with an increase in BoE or vice versa.
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inﬂuenced by changes in inhalation depth and duration. In con-
trast, a change in the degree of mouthspill could inﬂuence the
MLE/BoE relationship for all smoke constituents measured in the
study.
The slopes of the regressions and the correlations (r values) of
the MLEs versus corresponding BoEs (Table 8) were similar for
the control and switching groups. This indicates that switching to
a lower yield cigarette did not degrade the relationships between
MLEs and BoEs observed when the smokers were smoking their
usual brand of cigarette. This observation supports the use of either
the part-ﬁlter method or conventional biomarker methods for
determining the effects of brand-switching on the exposure of
smokers to cigarette smoke constituents.
Further evidence for the good relationship between the two ap-
proaches to the measurement of smoke constituent exposure was
the fact that for most smokers the changes in MLEs and BoEs for
the majority of the measured smoke constituents were in the same
direction following the switch to a lower yield cigarette (see Table
9). The exception was for acrolein exposure where directional
agreement between acrolein MLE and 3-HPMA was obtained in
only half of the smokers. This discrepancy between acrolein MLE
and the biomarker, 3-HPMA, is also shown in Table 6. Group 2
smokers reduced their mean acrolein MLE by 20% but mean 3-
HPMA was reduced by only 5% following the switch from the 10
to the 4 mg ISO tar cigarette. Mean acrolein MLE was increased
in group 4 smokers by 3% whereas mean 3-HPMA was reduced
by 32% following the switch from the 4 to the 1 mg ISO tar
cigarette.
Acrolein is semi-volatile and is found in both particulate and va-
pour phase, whereas the other smoke constituents measured in the
study are found predominantly in the particulate phase. The ana-
lytical method used for smoke acrolein involved a liquid trap and
therefore the measured acrolein yield includes both the particulate
and vapour phase components (total acrolein). This smoke yield is
plotted against nicotine retained on the ﬁlter tip to provide a cali-
bration curve to enable estimation of smoke yields from tip mea-
surements. However, it is possible that the calibration routine
used for determining MLEs for vapour phase components from
the part-ﬁlter method, especially for the highly ventilated 1 mg
ISO tar yield cigarette, may need to be improved.
Although, in general, the relationships between MLEs and their
corresponding BoEs were maintained when smokers switched
from their usual brand cigarettes to lower yield cigarettes there
were differences in the magnitudes of the changes in the two types
of exposure measures.
In group 2 smokers, switching from the 10 to the 4 mg ISO tar
cigarettes produced greater reductions in MLEs than in theircorresponding BoEs on a per cigarette basis. For example, mean
nicotine MLE was reduced by 29% whereas mean TNeq was re-
duced by 18%. As previously mentioned, factors such as changes
in the degree of mouthspill following the switch could possibly ac-
count for these differences in magnitude. The results would be con-
sistent with smokers reducing the degree of mouthspill when
switching from the 10 to the 4 mg tar yield cigarette. However,
the opposite effect was apparent in the group 4 smokers. In this in-
stance the reduction in mean MLEs tended to be less than those for
the corresponding BoEs following the switch from the 4 to the
1 mg ISO tar yield cigarette. For example, in group 4 mean nicotine
MLE decreased by 10% whereas TNeq decreased by 32% following
the switch. This would be consistent with the smokers increasing
the degree of mouthspill following the switch to the lower yield
cigarette although this seems an unlikely behavioural response.
An alternative explanation of the results could be that the part-ﬁl-
ter calibration method produced an underestimate of the MLEs for
the 4 mg ISO tar cigarette and an over-estimate of the MLEs for the
1 mg ISO tar cigarette. All but 0.1% of subject tip data for the 4 mg
(and 10 mg) ISO tar yield cigarettes were within calibration range
whereas for the 1 mg cigarette, 18.5% were above the calibration
and estimated from an extrapolation. Alternatively, measures of
TNeq could provide under or overestimates. Such aspects could be-
gin to account for the discrepancies between MLEs and BoEs in
both switching groups. In a previous study Shepperd et al. (2006)
compared nicotine and tar yields derived from ﬁlter analysis with
yields from a range of cigarettes smoked under a variety of dupli-
cated human pufﬁng proﬁles. They reported very good agreements
between the tar and nicotine yields from ﬁlter analysis and smok-
ing machines. However, the machine smoking regimes used for
calibrating the ﬁlter analysis method in that study were different
to those used in the current study.
Although the main aim of the product switch was to investigate
the relationships between MLEs and BoEs when smokers moved
from their usual product to a lower yield brand it is worthwhile
examining the data in the context of the phenomenon termed smo-
ker compensation.
Compensatory smoking can occur when a smoker switches
from a higher to a lower yield cigarette. Complete compensation
occurs when there is no reduction in a smoker’s exposure after
the switch, and zero compensation occurs when the proportional
reduction in exposure is the same as the proportional reduction
in machine-derived yield. Partial compensation describes the situ-
ation when the proportional reduction in exposure is less than the
proportional reduction in machine-derived yield (Scherer, 1999).
The degree of compensation can be inﬂuenced by a number of
potential human smoking behaviour factors. These include changes
in daily cigarette consumption, and pufﬁng topography variables
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cigarette consumption increased when both groups of smokers
(group 2 and 4) were switched from the higher to the lower yield
cigarettes. However, daily consumption increases were also seen in
their two non-switching, control groups (groups 1 and 3). As there
were no statistically signiﬁcant differences in consumption rates
between the switching groups and their controls in period 2 of
the study it is possible that these increases occurred as a result
of the experimental design rather than as a compensatory response
to the reduction in machine-derived yields in groups 2 and 4. This
suggests that it might be helpful to include non-switching control
groups in studies on compensatory smoking.
The compensation indices shown in Table 7 were based on nic-
otine exposure per cigarette data and thus were not inﬂuenced by
the systematic increase in daily cigarette consumption as the study
progressed. The nicotine BoE results indicated partial compensa-
tion occurred following the switches from the 10 to the 4 mg
(group 2), and the 4 to the 1 mg (group 4) tar yield cigarettes.
These observations are consistent with the partial compensation
ﬁndings based on nicotine uptake reported in the review articles
on smoker compensation (Stephen et al., 1989; Scherer, 1999)
and in more recent switching studies (Mendes et al., 2008; Beno-
witz et al., 2005). Our results from the group 4 smokers are also
in agreement with those of a recent Benowitz et al., (2009) study
which showed statistically signiﬁcant reductions in nicotine expo-
sure when smokers were progressively switched from their usual
brand (12 mg FTC tar yield) to 2 mg and 1 mg FTC tar yield brands.
However, Benowitz et al. (2009) did not observe a signiﬁcant
reduction in nicotine exposure when their subjects were switched
to a 4 mg FTC tar yield brand. Thus our results from the group 2
smokers are not consistent with those from the recent Benowitz
et al. (2009) study.
The compensation indices based on saliva cotinine were higher
than those based on plasma cotinine for both groups of switchers.
We currently have no plausible explanation for these differences.
In addition to the reductions in nicotine MLEs and BoEs, switch-
ing from a higher to a lower yield cigarette for a period of 12 days
resulted in statistically signiﬁcant reductions in MLEs for NNK
(both switching groups), pyrene (both switching groups) and acro-
lein (group 2) together with statistically signiﬁcant reductions in
the BoEs, NNAL (both groups), HPMA (group 4) and 1-OHP (group
4). Mendes et al. (2008) measured 24 h urinary nicotine equiva-
lents, plasma cotinine, NNAL, 1-OHP, 3-HPMA, S-PMA (biomarker
for benzene) and COHb in smokers in short (8 days) and long-term
switching (24 weeks) from US Marlboro full ﬂavour (MFF 15 mg
FTC tar yield) to either Marlboro Lights (ML 11 mg FTC tar yield)
or Marlboro Ultra Lights (MUL 6 mg FTC tar yield). They com-
pared the results from the two switching groups with those from
a control group who smoked MFF throughout the study. Switching
from MFF to ML produced small but statistically signiﬁcant reduc-
tions in 24 h urinary nicotine equivalents and 1-OHP but no reduc-
tion in the other measured biomarkers following the short-term
switch. Short-term switching from MFF to MUL resulted in statis-
tically signiﬁcant reductions in 24 h urinary nicotine equivalents,
plasma cotinine, NNAL and 1-OHP, and non-signiﬁcant reductions
in the other biomarkers. Our 12-day switching results are broadly
in line with the short-term switching data reported by Mendes
et al. (2008).
Benowitz et al. (2005) conducted a short-term switching study
(1 week) in which US smokers were switched from their usual cig-
arette to one delivering around 50% less nicotine under standard
machine-smoking conditions. The average machine-derived yields
for own brand cigarettes were 14.4 mg FTC tar, 1.06 mg FTC nico-
tine for the pre-switch brands and 6.1 mg FTC tar, 0.5 mg FTC nic-
otine for the post-switch brands. Benowitz et al. (2005) reported
small reductions in nicotine BoEs in spot urine samples(normalised by creatinine) but no reductions in NNAL or biomark-
ers of pyrene exposure. They concluded that short-term switching
to lower yield brands produced no signiﬁcant reduction in carcin-
ogen exposure. In a more recent study Benowitz et al. (2009) grad-
ually switched smokers from their usual brand (average yields
12.1 mg tar, 1.05 mg nicotine) to ﬁve brands with progressively re-
duced tar and nicotine yields. Each brand was smoked for a period
of 1 week and BoEs for nicotine, NNK, pyrenes (spot urine samples)
and CO were measured. They reported no signiﬁcant reductions in
the various biomarkers for three of the cigarettes (12, 8 and 4 mg
tar yield) but signiﬁcant reductions in the BoEs were obtained for
the 2 and 1 mg tar yield cigarettes compared with the exposures
obtained from the smokers’ usual brands. Our MLE and BoE results
following the switch from a 4 to a 1 mg ISO tar yield cigarette are in
line with those reported by Benowitz et al. (2009). However, we
also observed statistically signiﬁcant reductions in NNK and pyr-
ene MLEs, and NNAL following a switch from a 10 to a 4 mg ISO
tar cigarette whereas Benowitz et al. (2009) failed to observe dif-
ferences in NNAL or BoEs for pyrene when their subjects switched
down to a 4 mg FTC tar yield cigarette. Spot urine samples should
have higher variability than the 24 h urine samples collected in a
clinic. Therefore, this may explain why Benowitz failed to detect
differences that were detected by both Mendes and the current
study. An additional problem with the Benowitz et al. (2009) study
is that the yields of NNK and pyrene were not measured in any of
the cigarettes used in the study. Thus there is no information to
show the magnitude of the differences in the machine-derived
yields of these constituents between the pre- and post-switch cig-
arettes. In contrast, machine-derived yields of the constituents
relating to the various MLEs and BoEs were measured in our study,
and the three products differed markedly in the yields of NNK and
pyrene.
Another interesting observation in the data from our study is
that following the switch from the 10 to the 4 mg ISO tar yield
cigarettes the group 2 mean values for nicotine, NNK, acrolein,
and pyrene MLEs, and TNeq, NNAL and 1-OHP were very similar
to those obtained by the regular smokers of 4–5 mg ISO tar yield
cigarettes (i.e. group 3 smokers). A similar outcome was seen
following the switch from the 4 to the 1 mg ISO tar cigarette.
In this instance post-switch mean values for nicotine, NNK and
pyrene MLEs, NNAL, 3-HPMA and 1-OHP were similar to those
measured in the regular 1–2 mg ISO tar yield smokers. These
observations are consistent with those published by Mendes
et al. (2008) who reported similar levels of nicotine BoEs in
smokers who switched from Marlboro full ﬂavour to Marlboro
Lights in the short-term phase of their study to those obtained
from regular smokers of Marlboro Lights measured in an earlier
study (Roethig et al., 2007). Mendes et al. (2008) reported that
such results supported the validity of forced switching studies
to evaluate exposure to different cigarette products. Our results
are consistent with the work reported by Mendes et al. (2008).
These data, of course, provide no information on whether the
reductions in MLEs or BoEs are associated with any reductions
in health risks.
In conclusion, our study has demonstrated that MLEs for nico-
tine and other smoke constituents derived from the analysis of
spent ﬁlters are related to BoEs during short-term brand switch
studies. Although the pre- to post-switch directional changes in
MLEs and their corresponding BoEs were consistent for most of
the smoke constituents measured there were some differences in
the magnitudes of the changes observed using the two methods
of exposure assessment. Further work is required to determine
whether these anomalies occurred as a result of post-puff inhala-
tion changes e.g., degree of mouthspill, or as a result of calibration
issues particularly with highly ventilated, very low tar yield
cigarettes.
S24 C.J. Shepperd et al. / Regulatory Toxicology and Pharmacology 61 (2011) S13–S24Conﬂict of Interest Statement
This work was funded by British American Tobacco (BAT), and
all authors, with the exception of Dr. Mike Dixon, are full time
employees of BAT. Dr. Mike Dixon’s involvement was in the capac-
ity of a paid consultant to BAT.
Acknowledgments
We thank Dr. Gerhard Scherer and Dr. Kelley St. Charles for
their input into the study design and Pamela Saunders and Made-
leine Ashley for their contribution to the ﬁlter analysis and Dr.
Christopher Proctor for his contribution to the draft manuscript.
References
Armitage, A.K., Dollery, C.T., George, C.F., Houseman, T.H., Lewis, P.J., Turner, D.M.,
1975. Absorption and metabolism of nicotine from cigarettes. Br. Med. J. 4
(5992), 313–316.
Armitage, A.K., Dixon, M., Frost, B., Mariner, D.C., Sinclair, N.M., 2004. The effect of
inhalation volume and breath-hold on the retention of nicotine and solanesol in
the human respiratory tract and subsequent plasma nicotine concentration
during cigarette smoking. Beitr. Tabakforsch. Int. 21 (4), 240–249.
Ashley, D.L., O’Connor, R.J., Bernert, J.T., et al., 2010. Effect of differing levels of
tobacco speciﬁc nitrosamines in cigarette smoke on the levels of biomarkers in
smokers. Cancer Epidemiol Biomarkers Prev 19 (6), 1389–1398.
Baker, R.R., Dixon, M., 2006. The retention of tobacco smoke constituents in the
human respiratory tract. Inhal. Toxicol. 18 (4), 255–294.
Benowitz, N.L., Jacob III, P., Bernert, J., Wilson, M., Wang, L., Allen, F., Dempsy, D.,
2005. Carcinogen exposure during short-term switching from regular to light
cigarettes. Cancer Epidemiol Biomarkers Prev 14, 1376–1383.
Benowitz, N.L., Dains, K.M., Hall, S.M., Stewart, S., Wilson, M., Dempsey, D., Jacob III,
P., 2009. Progressive commercial cigarette yield reduction: Biochemical
exposure and behavioral assessment. Cancer Epidemiol Biomarkers Prev 18,
876–883.
Bridges, R.B., Combs, J.G., Humble, J.W., Turbeck, J.A., Rehms, R., Haley, N.J., 1990.
Population characteristics and cigarette yield as determinants of smoke
exposure. Pharmacol. Biochem. Behav. 37, 17–28.
Byrd, G.D., Davis, R.A., Caldwell, W.S., Robinson, J.H., deBethizy, J.D., 1998. A further
study of FTC yield and nicotine absorption in smokers. Psychopharmacology
134, 291–299.
Commonwealth of Massachusetts 1997. Tobacco disclosure act, General laws of
Massachusetts, Chapter 94, Section 307B, 105 CMR 660.000, Cigarette and
smokeless tobacco products: Reports of added constituents and nicotine
ratings. <www.mass.gov/Eeohhs2/docs/dph/regs/105cmr660.pdf>.
Ebert, R.V., McNabb, M.E., McCusker, K.T., Snow, S.L., 1983. Amount of nicotine and
carbon monoxide inhaled by smokers of low tar, low nicotine cigarettes. JAMA
250, 2840–2842.
Feng, S., Plunkett, S.E., Lam, K., Kapur, S., Muhammad, R., Jin, Y., Zimmermann, M.,
Mendes, P., Kinser, R., Roethig, H.J., 2007. A new method for estimating the
retention of selected smoke constituents in the respiratory tract of smokers
during cigarette smoking. Inhal. Toxicol. 19, 169–179.
Gori, G.B., Lynch, C., 1985. Analytic cigarette yields as predictors of smoke
bioavailability. Reg. Toxicol. Pharmacol. 5, 314–326.
Hecht, S.S., Murphy, S.E., Carmella, S.G., Li, S., Jensen, J., Le, C., Joseph, A.M.,
Hatsukami, D.K., 2005. Similar uptake of lung carcinogens by smokers of
regular, light, and ultralight cigarettes. Cancer Epidemiol. Biomarkers Prev. 14,
693–698.
Jarvis, M., Boreham, P.P., Feyerabend, C., Bryant, A., 2001. Nicotine yield from
machine-smoked cigarettes and nicotine intake from smokers: evidence from a
representative population survey. J. Nat. Cancer Inst. 93 (2), 134–138.Mendes, P., Kapur, S., Wang, J., Feng, S., Roethig, H., 2008. A randomized, controlled
exposure study in adult smokers of full ﬂavor Marlboro cigarettes switching to
Marlboro lights or Marlboro ultra lights cigarettes. Regul. Toxicol. Pharmacol.
51 (3), 295–305.
Mendes, P., Liang, Q., Frost-Pineda, K., Munjal, S., Walk, R.A., Roethig, H., 2009. The
relationships between smoking machine derived tar yields and biomarkers of
exposure in adult cigarette smokers in the US. Regul. Toxicol. Pharmacol. 55,
17–27.
Moldoveanu, S.C., St. Charles, F.K., 2007. Differences in the chemical composition of
the particulate phase of inhaled and exhaled cigarette mainstream smoke. Beitr.
Tabakforsch. Int. 22, 290–302.
Moldoveanu, S.C., Coleman III, W., Wilkins, J.M., 2008. Determination of polycyclic
aromatic hydrocarbons in exhaled cigarette smoke. Beitr. Tabakforsch. Int. 23,
85–97.
Pauly, J.L., O’Connor, R.J., Paszkiewicz, M., Cummings, K.M., Djordjevic, M.V., Shields,
P.G., 2009. Cigarette ﬁlter-based assays as proxies for toxicant exposure and
smoking behavior – A literature review. Cancer Epidemiol. Biomarkers Prev. 18
(12), 3321–3333.
Polzin, G.M., Wu, W., Yan, X., McCraw, J.M., Abdul-Salaam, S., Tavakoli, A.D., Zhang,
L., Ashley, D.L., Watson, C.H., 2009. Estimating smokers’ mouth level xposures to
select mainstream smoke constituents from discarded cigarette ﬁlter butts.
Nicotine & Tob. Res. 11, 868–874.
Roethig, H.J., Zedler, B.K., Kinser, R.D., Feng, S., Nelson, B.L., Liang, Q., 2007. Short-
term clinical expaoure evaluation of second-generation electrically heated
cigarette smoking system. J. Clin. Pharmacol. 47, 518–530.
Rosa, M., Paciﬁci, R., Altieri, I., Pichini, S., Ottaviani, G., Zuccaro, P., 1992. How the
steady state cotinine concentration in cigarette smokers is directly related to
nicotine intake. Clin. Pharmacol. Ther. 52, 324–329.
Russell, M.A.H., Jarvis, M., Iyer, R., Feyerabend, C., 1980. Relation of nicotine yield of
cigarettes to blood nicotine concentrations in smokers. Br. Med. J. 280, 972–976.
Russell, M.A.H., Jarvis, M.J., Feyerabend, C., Saloojee, Y., 1986. Reduction of tar,
nicotine and carbon monoxide intake in low tar smokers. J. Epidemiol.
Commun. Health 40, 80–85.
Scherer, G., 1999. Smoking behavior and compensation: a review of the literature.
Psychopharmacology 145, 1–20.
Scherer, G., Urban, M., Engl, J., Hagedorn, H.-W., Riedel, K., 2006. Inﬂuence of
smoking charcoal ﬁlter tipped cigarettes on various biomarkers of exposure.
Inhal. Toxicol. 18, 821–829.
Scherer, G., Engl, J., Urban, M., Gilch, G., Janket, D., Riedel, K., 2007. Relationship
between machine-derived smoke yields and biomarkers in cigarette smokers in
Germany. Regul. Toxicol. Pharmacol. 47, 171–183.
Shepperd, C.J., St. Charles, F.K., Lien, M., Dixon, M., 2006. Validation of methods for
determining consumer smoked cigarette yields from cigarette ﬁlter analysis.
Beitr. Tabakforsch. Int. 22, 176–184.
Shepperd, C.J., Eldridge, A.C., Mariner, D.C., McEwan, M., Errington, G., Dixon, M.,
2009. A study to estimate and correlate cigarette smoke exposure in smokers in
Germany as determined by ﬁlter analysis and biomarkers of exposure. Regul.
Toxicol. Pharmacol. 55, 97–109.
St. Charles, F.K., Krautter, G.R., Dixon, M., Mariner, D.C., 2006. A comparison of
nicotine dose estimates in smokers between ﬁlter analysis, salivary cotinine,
and urinary excretion of nicotine metabolites. Psychopharmacology 189 (3),
345–354.
St. Charles, F.K., Kabbani, A.A., Borgerding, M.F., 2010. Estimating tar and nicotine
exposure: human smoking versus machine smoking. Regul. Toxicol. Pharmacol.
56 (1), 100–110.
Stephen, A., Frost, C., Thompson, S., Wald, N., 1989. Estimating the Extent of
Compensatory Smoking. In: Wald, N., Froggatt, P. (Eds.), Nicotine, Smoking and
the Low Tar Programme. Oxford Medical Publications, Oxford, pp. 100–115.
Ueda, K., Kawach, I., Nakamura, M., Nogami, H., Shirokawa, N., Masui, S., Okayama,
A., Oshima, A., 2002. Cigarette nicotine yields and nicotine intake among
Japanese male workers. Tob. Control 11, 55–60.
Zacny, J.P., Stitzer, M.L., Brown, F.J., Yingling, J.E., Grifﬁths, R.R., 1987. Human
cigarette smoking: effects of puff and inhalation parameters on smoke
exposure. J. Pharmacol. Exp. Ther. 240, 554–564.
